C Michael Gibson/Baim Institute
Feb 16, 2026, 06:21
C. Michael Gibson: Favorable Safety Outcomes With Asundexian
C. Michael Gibson, President and CEO at Baim Institute for Clinical Research, Professor of Medicine at Harvard Medical School, and Executive Board Member at EXCITE International, shared a post on LinkedIn:
”No increase in any type of bleeding with Asundexian. Even minor bleeding was not increased (was numerically lower).”
Stay updated with Hemostasis Today.
-
May 26, 2026, 10:04Dima Shulkin: A Novel Monocyte-Based Biomarker of Cardiovascular Risk
-
May 26, 2026, 09:42Wael AlAnazi: Exceptional HLA-Matched Transplant Outcomes With Novel Thiotepa-Based Conditioning
-
May 26, 2026, 09:31Vanduyn Hoven Sibarani: Impact of Pac Dosing on Raw Water Coagulation Performance
-
May 26, 2026, 09:30Sivasooriar Sivaneson: Every Drop of Blood Matters in Pre-Analytical Laboratory Quality
-
May 26, 2026, 08:11Shady Abohashem։ Stress, Hormones, and Cardiovascular Risk in Women
-
May 26, 2026, 07:39Abdulrahman Nasiri: Managing Refractory Severe Aplastic Anemia During Pregnancy
-
May 26, 2026, 07:21Eman Badr: From Platelets to Precision Oncology
-
May 26, 2026, 07:12Jenish Christin: The Clot Buster That Buys Time in Critical Moments
-
May 26, 2026, 06:43Francisco Epelde: Cardiac Lymphatic System as an Active Regulator of Myocardial Homeostasis